Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade A 22.65 -0.74% -0.17
EXEL closed down 0.74 percent on Friday, January 18, 2019, on 1.42 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical EXEL trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 NR7-2 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.74%
Jan 17 NR7 Range Contraction -0.74%
Jan 17 Wide Bands Range Expansion -0.74%
Jan 17 Overbought Stochastic Strength -0.74%

Older signals for EXEL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Is EXEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.79
52 Week Low 13.42
Average Volume 4,186,321
200-Day Moving Average 19.5113
50-Day Moving Average 19.902
20-Day Moving Average 21.158
10-Day Moving Average 23.199
Average True Range 1.058
ADX 29.08
+DI 27.4684
-DI 16.1587
Chandelier Exit (Long, 3 ATRs ) 21.076
Chandelier Exit (Short, 3 ATRs ) 20.314
Upper Bollinger Band 25.5578
Lower Bollinger Band 16.7582
Percent B (%b) 0.67
BandWidth 41.589942
MACD Line 1.0506
MACD Signal Line 0.9801
MACD Histogram 0.0705
Fundamentals Value
Market Cap 6.66 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 113.25
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.85
Resistance 3 (R3) 23.84 23.44 23.65
Resistance 2 (R2) 23.44 23.13 23.44 23.58
Resistance 1 (R1) 23.04 22.94 22.84 23.05 23.52
Pivot Point 22.64 22.64 22.54 22.64 22.64
Support 1 (S1) 22.24 22.33 22.04 22.25 21.78
Support 2 (S2) 21.84 22.14 21.84 21.72
Support 3 (S3) 21.44 21.84 21.65
Support 4 (S4) 21.45